The high incidence of these tumor types, coupled with the availability of well-characterized circulating biomarkers such as HER2, PSA, and CEA, makes them exemplary reference models for validating liquid biopsy platforms that incorporate photonic biosensing technologies. Here, ERBB2 is linked to neoplasm.